new glp 1 drugs 2025 Indications for GLP-1/GIP RA Summary Sheet and Beyond! fda warning glp-1 october 2025

Usual Adult Trulicity Dose for Cardiovascular Risk Reduction: Initial dose: Trulicity 0.75 mg subcutaneously once a week The dose may be increased to 1.5 from 0.75, then in 1.5 mg increments for additional glycemic control

Between 2023 and 2027, the market is poised to increase by US$ 36.5 billion

Retrieved March 10, 2026, from The four states that removed coverage of GLP-1 AOMs for weight loss collectively spent approximately $2.5 billion on Wegovy, Zepbound, and Saxenda in a 30-month span, on a gross basis for all indications

Their research has also solved a mystery that began more than a century ago

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

In conclusion, glyceollins function as GLP-1 receptor agonists and may also aid in the prevention of prostate cancer in women [34]